Clinical Trial Update: Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating iparomlimab and tuvonralimab (QL1706) in combination with albumin-bound paclitaxel and lenvatinib as second-line therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer | Phase 2 | Status: RECRUITING